Sumit Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.24 M
- Company Age 38 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.10 Cr
- Revenue Growth -10.44%
- Profit Growth -9.35%
- Ebitda -476.40%
- Net Worth 11.06%
- Total Assets -22.88%
About Sumit Pharmaceuticals
Sumit Pharmaceuticals Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 July 1986 and has a history of 38 years and seven months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.24 M.
The company currently has active open charges totaling ₹1.10 Cr.
Sanjeev Agarwal and Anshu Agarwal serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U29297UP1986PTC008040
- Company No.
008040
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 1986
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Sumit Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Agarwal  | Whole-Time Director | 23-May-1992 | Current |
| Anshu Agarwal | Director | 27-Dec-2010 | Current |
Financial Performance of Sumit Pharmaceuticals.
Sumit Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 10.44% decrease. The company also saw a slight decrease in profitability, with a 9.35% decrease in profit. The company's net worth Soared by an impressive increase of 11.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sumit Pharmaceuticals?
In 2018, Sumit Pharmaceuticals had a promoter holding of 92.44% and a public holding of 7.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.00 Cr
- Union Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jun 2012 | Union Bank Of India | ₹1.00 M | Open |
| 21 Jan 2011 | Others | ₹1.00 Cr | Open |
How Many Employees Work at Sumit Pharmaceuticals?
Unlock and access historical data on people associated with Sumit Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sumit Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sumit Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
